One Vaccine Against 3 Viruses: Promising Results Could Shift Respiratory Prevention

2026-07-05T22:19:24.213Z

A study published in the journal Science Advances reported that an experimental single-dose vaccine, based on CoPoP particles, stimulated protective immunity against seasonal influenza, COVID-19, and respiratory syncytial virus in experiments on mice and ferrets, with antibody responses similar to single-virus vaccines, while emphasizing the need for further studies.

Researchers at the University of New York in Buffalo have revealed an experimental single-dose vaccine that shows promising potential to provide protection against three major respiratory viruses at once, a step that could change the future of immunization against respiratory diseases.

The study, published in the journal Science Advances, explained that the triple vaccine stimulated a protective immune response against seasonal influenza, COVID-19, and respiratory syncytial virus in laboratory mice and ferrets.

Jonathan Lovell, the research team leader, said: 'The antibody response was similar to that produced by vaccines that target only one virus, indicating that combining the three vaccines into a single dose did not weaken their effectiveness.'

The vaccine is based on the CoPoP technology, consisting of tiny spherical particles made of cobalt and porphyrin, covered by a phospholipid shell. Viral proteins attached to these particles help train the immune system to recognize and fight the three viruses.

This approach differs from the most widespread COVID-19 vaccines that rely on mRNA technology, as the new vaccine uses viral proteins directly instead of genetic instructions.

The researchers emphasized the need for additional studies to determine whether interactions between the different vaccine components could affect the immune response when doses are altered, noting that the trials are still in early stages on animals.

Lovell expressed hope to 'expand the scope of this platform to provide protection against a broader spectrum of respiratory viruses in the future.'